辛伐他汀与曲美他嗪联合治疗不稳定型心绞痛疗效观察被引量：7

下载PDF

导出

摘要【目的】探讨辛伐他汀与曲美他嗪联合治疗不稳定型心绞痛(UA)的临床疗效。【方法】将120例UA随机分成两组,对照组常规治疗,治疗组在常规治疗基础上口服辛伐他汀40 mg,1次/d;曲美他嗪20mg,3次/d,观察治疗后心绞痛缓解、心电图改善、血脂变化及不良反应。【结果】治疗组的总有效率明显高于对照组(P<0.05),治疗组治疗后TC、LDL-C较治疗前明显降低(P<0.01),HDL-C较治疗前明显升高(P<0.01),而对照组治疗后TC、LDL-C高于治疗组,HDL-C低于治疗组(P<0.05)。【结论】辛伐他汀与曲美他嗪联合治疗UA安全有效,能显著降低血脂,心绞痛临床缓解,心电图明显改善。

作者龚立三汤益坤

机构地区湖南省南县人民医院

出处《医学临床研究》 CAS 2006年第8期1298-1300,共3页 Journal of Clinical Research

关键词心绞痛不稳定性/药物疗法斯伐他汀/治疗应用曲美他嗪/治疗应用

分类号 R541.405 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量：2695
2梁春,吴宗贵.他汀类药物调脂治疗的昨天、今天和明天[J].上海医学,2005,28(4):270-273. 被引量：3
3赵水平.他汀类药物调脂治疗[J].中国实用内科杂志,2003,23(8):510-511. 被引量：40
4Takemoto M,Liao JK.Pleiotropic effects of 32hydroxy232methylglutaryl coenzyme a reductase inhibitors[J].Arterioscler Thromb Vasc Biol,2001,21:1712-1719. 被引量：1
5StanleyWC,Lopaschuk GD,Hall JL,et al.Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions[J].Cardiovase Res,1997; 33:243-257. 被引量：1
6吕勇,王尊,刘振东,邱振梅,张军华.曲美他嗪联合常规疗法治疗不稳定型心绞痛疗效观察[J].山东医药,2002,42(21):41-41. 被引量：48
7Lopaschuk GD.Trimetazidine inhibits fatty acid oxidation in the heart[J].J Mol Cell Cardiol,1998; 30(1):122-126. 被引量：1

二级参考文献15

1Spencer FA, Allegrone J, Goldberg RJ,et al. Association of statin therapy with outcomes of acute coronary syndromes:the GRACE study. Ann Intern Med. 2004,140:857-866. 被引量：1
2Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001,285:1711-1718. 被引量：1
3Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med,2004, 350:1495-1504. 被引量：1
4Blazing MA, De Lemos JA, Dyke CK,et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J, 2001, 142:211-217. 被引量：1
5Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). JAMA, 2001,285:2486-2497. 被引量：1
6Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation, 1999,99:3241-3247. 被引量：1
7McCormick LS, Black DM, Waters D, et al. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol,1997,80:1130-1133. 被引量：1
8Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. Circulation,2004,110:227-239. 被引量：1
9Barth JD, Zonjee MM. Regression growth evaluation statin study (REGRESS) : study design and baseline characteristics in 600 patients. The REGRESS Research Group. Can J Cardiol, 1992,8 : 925-932. 被引量：1
10Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004,291:1071-1080. 被引量：1